SRR1323174
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.394
- PANCREAS_BETA_CELLS+0.377
- BILE_ACID_METABOLISM+0.228
- ESTROGEN_RESPONSE_LATE+0.218
- ESTROGEN_RESPONSE_EARLY+0.215
- MYOGENESIS+0.202
- COAGULATION+0.197
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.188
- NOTCH_SIGNALING+0.183
- XENOBIOTIC_METABOLISM+0.158
Top 10 suppressed
- MYC_TARGETS_V1-0.638
- PROTEIN_SECRETION-0.553
- MYC_TARGETS_V2-0.541
- UNFOLDED_PROTEIN_RESPONSE-0.488
- DNA_REPAIR-0.475
- E2F_TARGETS-0.448
- OXIDATIVE_PHOSPHORYLATION-0.414
- MTORC1_SIGNALING-0.379
- MITOTIC_SPINDLE-0.373
- G2M_CHECKPOINT-0.367
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1352975 | GTEX | — | 0.944 |
| 2 | TCGA-ZF-A9R0-01A-11R-A38B-07 | — | — | 0.944 |
| 3 | SRR1499193 | GTEX | — | 0.942 |
| 4 | SRR1381673 | GTEX | — | 0.942 |
| 5 | SRR1336069 | GTEX | — | 0.941 |
| 6 | SRR1333352 | GTEX | — | 0.939 |
| 7 | BS_AKRHBPNZ | Ganglioglioma | — | 0.936 |
| 8 | SRR1396640 | GTEX | — | 0.934 |
| 9 | SRR1361674 | GTEX | — | 0.930 |
| 10 | MNG768 | — | — | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.394 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.377 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.228 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.218 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.215 | Inavolisib | — uncovered |
| MYOGENESIS | 0.202 | Inavolisib | — uncovered |
| COAGULATION | 0.197 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.188 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.183 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.158 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.125 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.079 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.044 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.038 | Remibrutinib | — uncovered |
| HYPOXIA | 0.038 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.011 | Inavolisib | — uncovered |